Is Urolithin A Legal in Your Market?

For companies sourcing Urolithin A(UA) for supplements or cosmetics, meeting the ingredient specification is only part of the equation. A product can meet its stated purity and quality requirements but still face regulatory issues when it comes to import, product classification, labeling, safety documentation, or market claims.

This is where Urolithin A sourcing becomes more complicated. Requirements can vary significantly by market, and factors such as the production route, ingredient specifications, safety data, certificates, and intended use may all affect whether a UA ingredient can be legally imported and used in a finished product.

For buyers, regulatory readiness should be checked before an order is placed-not after the shipment arrives or the formulation is completed. This guide reviews the key regulatory considerations for Urolithin A in major markets, the compliance points buyers should pay attention to, and the documents worth requesting from suppliers before moving forward.

Global Market Access: Regulatory Status Across Key Regions

North America (US & Canada): Navigating GRAS and NDI Boundaries

In the United States, dietary supplement ingredients must either be established pre-DSHEA dietary ingredients or obtain New Dietary Ingredient (NDI) notification or Generally Recognized as Safe (GRAS) status.

For Urolithin A, achieving GRAS status-either through self-affirmation or formal FDA GRN (GRAS Notice) submission-provides the primary framework for legal inclusion in conventional foods and dietary supplements. Under FDA guidelines, GRAS notices for Urolithin A specify clear application boundaries:

• Approved Delivery Formats: Standard capsules, tablets, functional beverages, and protein bars.
• Daily Intake Thresholds: Generally capped at 250 mg to 500 mg per serving for general adult populations [1].

Exceeding specified serving thresholds or introducing Urolithin A into unapproved delivery vehicles without additional toxicology data exposes a brand to FDA warning letters or product recalls.

Europe (EU & UK): Novel Food Authorizations and Strict Dose Caps

The European Food Safety Authority (EFSA) enforces strict oversight under the Novel Food Regulation (EU) 2015/2283. Urolithin A holds Novel Food authorization, but its scope is tightly regulated [2]:

• Target Applications

Restricted primarily to dietary supplements for adults, excluding pregnant and lactating women.

• Acceptable Daily Intake (ADI)

Capped at a strict maximum of 500 mg per day for general adult populations, with lower proportional limits if incorporated into specialized meal replacements.

• Specification Compliance

EFSA mandates exact limits on purity levels and structural identity, meaning any deviation in raw material specifications requires a separate Novel Food dossier submission.

China & APAC: Cosmetic Filings and Oral Import Trends

In China, oral Urolithin A currently operates outside the standard Positive List for general health foods, making cross-border e-commerce (CBEC) the primary pathway for oral supplement brands.

Conversely, the topical cosmetic sector presents distinct opportunities. Under the National Medical Products Administration (NMPA) framework for New Cosmetic Ingredients (NCI), Urolithin A requires comprehensive toxicology screening, including:

• Ames mutagenicity testing
• Acute skin irritation and phototoxicity evaluations
• 28-day or 90-day repeated-dose dermal toxicity studies

Clearing NMPA technical review allows brands to position Urolithin A as an advanced anti-aging topical active, provided skin-barrier absorption and stability data support the filing.

Global Compliance Matrix for Urolithin A

Production Route and Quality Audit: Synthetic vs. Enzymatic Fermentation

The Regulatory Risk of Synthetic vs. Enzymatic Synthesis

The manufacturing process used to synthesize Urolithin A directly dictates regulatory approval validity. EFSA and FDA filings are tied to explicit production routes:

If an ingredient supplier alters their synthesis pathway-transitioning from a bio-enzymatic reaction to a lower-cost chemical synthesis route-the raw material no longer complies with established GRAS or Novel Food filings. Utilizing an unapproved synthesis route invalidates product registration, exposing importers to border detentions and regulatory enforcement.

At Botanical Cube, we utilize a proprietary directed enzymatic reaction process. By mimicking natural gut microbiome metabolic pathways under controlled conditions, this process eliminates harsh industrial reagents, yields a consistent crystalline structure, and maintains total alignment with global regulatory specifications.

Technical Specification Audit: Reading the COA

Relying solely on an overall purity percentage (Assay >= 98.0%) is insufficient for regulatory clearance. Customs authorities and third-party auditors examine specific contaminant thresholds:

• Residual Solvents (GC-MS)

Class 1 solvents (such as Benzene) must be completely absent. Class 2 solvents (such as Methanol, Toluene) must fall significantly below ICH Q3C guidelines (e.g., Methanol < 3000 ppm; Toluene < 890 ppm).

• Related Impurities (HPLC Area Percent)

Individual unidentified single impurities must remain below 0.10%, with total impurities capped under 1.50%. Unidentified chromatographic peaks often trigger regulatory inquiries regarding potential mutagenic intermediates.

• Heavy Metal Limits (ICP-MS): Stringent limits are enforced across target markets:

Lead (Pb): < 0.5 ppm

Arsenic (As): < 1.0 ppm

Cadmium (Cd): < 0.5 ppm

Mercury (Hg): < 0.1 ppm

On-Pack Claims: Structure/Function vs. Disease Claims

Translating the biological mechanism of Urolithin A into compliant packaging claims requires strict adherence to regional labeling regulations.

Oral Supplements

While clinical literature demonstrates that Urolithin A activates mitophagy and improves mitochondrial bioenergetics [3], packaging copy must avoid disease-mitigation claims.

• Non-Compliant (Disease Claim): "Reverses age-related muscle atrophy, cures mitochondrial dysfunction, and prevents sarcopenia."
• Compliant (Structure/Function Claim): "Supports cellular renewal, promotes healthy mitochondrial function, and aids muscle strength and endurance."

Topical Cosmetics

For cosmetic applications, anti-aging claims must focus on physical skin appearance and cellular rejuvenation metrics rather than physiological alteration.

• Non-Compliant: "Penetrates deep tissue to permanently alter cellular senescence and repair cellular damage."
• Compliant: "Revitalizes skin appearance, reduces the look of fine lines by supporting skin cell energy, and enhances skin firmness."
• Commerical Procurement Checklist: Technical Dossier Requirements

Before issuing a Purchase Order or approving a production sample, verify that your raw material manufacturer provides a complete Technical Regulatory Dossier.

Essential Technical Dossier Documents

• Certificate of Analysis (COA): Batch-specific, detailing Assay, Heavy Metals, Residual Solvents, and Microbials.
• Method of Analysis (MOA): Validated HPLC and GC testing methods for in-house quality verification.
• Flow Chart of Manufacturing: Step-by-step process disclosure including starting materials, catalysts, and purification steps.
• Stability Testing Data: 6-month accelerated (40 degrees C +/- 2 degrees C / 75% RH +/- 5% RH) and 24-month real-time stability reports.
• Safety & Toxicology Packet: Acute oral toxicity, Ames test, and chromosome aberration test reports.
• Regulatory Declarations: Non-GMO, Allergen-Free, BSE/TSE-Free, Residual Solvent Declaration, and Irradiation-Free certificates.

To streamline product development for our brand partners, Botanical Cube maintains fully compiled, ready-to-file Technical Dossiers for our high-purity Urolithin A powder. This documentation enables compliance teams to accelerate regulatory filings without extended technical delays.

Commercial Evidence: Formulations and Supply Chain Stability

Securing market approval requires both regulatory compliance and long-term technical stability.

Formulation and Bioavailability Benchmarks

In human clinical trials, Urolithin A supplementation at 500 mg daily demonstrated a statistically significant 2-fold increase in plasma Urolithin A glucuronide levels compared to baseline, correlating with improved mitochondrial biomarker expression in muscle tissue [3].

In topical skin formulations, raw Urolithin A exhibits limited water solubility. To resolve this, technical studies confirm that micro-encapsulation or liposomal delivery systems enhance dermal penetration depth, stabilizing the active ingredient within oil-in-water emulsions without causing color shifting or precipitation over time.

Supply Chain and Manufacturing Reliability

Consistent quality and reliable supply are critical when scaling Urolithin A from samples to commercial production. Botanical Cube operates cGMP-certified manufacturing facilities with automated enzymatic reaction tanks and continuous crystallization systems. Multi-ton production capacity and validated analytical testing support stable specifications and batch-to-batch consistency.

Commercial Support and Technical Consultation

Market requirements can vary by country, making complete technical documentation an important part of supplier qualification. Botanical Cube provides COAs, heavy metal profiles, stability data, and sample dossiers to support quality review and regulatory preparation.For detailed specifications, technical documents, custom requirements, or a laboratory-tested Urolithin A sample, contact our technical sales team at sales@botanicalcube.com.

References

[1] U.S. Food and Drug Administration. Agency Response Letter GRAS Notice No. GRN 000791: Urolithin A. FDA Center for Food Safety and Applied Nutrition (2018). (Referenced in Global Market Access: North America Section)

[2] EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of Urolithin A as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 18(1): 5969 (2020). (Referenced in Global Market Access: Europe Section)

[3] Andreux, P. A., et al. The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1(6): 595-603 (2019). (Referenced in Formulation and Bioavailability Benchmarks Section)